The Art of Model-Informed Narratives

Translating Differential Equations into Regulatory Certainty

In the high-stakes world of Model-Informed Drug Development (MIDD), the “story” is the data. I specialise in bridging the gap between the compartmental model and the peer-reviewed journal. Far from just editing, I do understand the underlying pharmacometrics, ensuring that the structural integrity of your model is preserved in every sentence of the manuscript.

Pharmacometrics First: Why I Understand Your Model

I approach scientific writing from the perspective of the modeller, not just the editor. Having been mentored by Dr. Phil Lowe (ex-Novartis), I understand that a manuscript isn’t just a report, it’s a logical proof of a drug’s behaviour.

1. Mastering the Calculus of Drug Action

I recognise that the power of PKPD lies in its predictive mathematics. My methodology is built on a foundational understanding of:

Differential Calculus: I understand how rates of change define the movement of a drug through physiological compartments.
Compartmental Modeling: Whether dealing with one, two, or three-compartment models, I ensure the narrative accurately reflects the volume of distribution ( $V_d$ ) and clearance ( $CL$ ) parameters.
The Power of MIDD: I frame your data within the context of Model-Informed Drug Development, showing regulators how simulations can optimise dose selection and reduce clinical trial risk.

2. Software & Tooling Fluency

A professional science writer should be comfortable in the environment where the science happens. I am familiar with the outputs and logic of the industry-standard toolsets:

- Non-linear Mixed Effects Modeling (NONMEM): I understand the transition from raw data to population PK analysis.
- Simulations & Sensitivity: I can translate complex sensitivity analyses and Monte Carlo simulations into clear, actionable insights for non-modelling stakeholders.
- Strategic Publication: My work has supported major papers in CPT: Pharmacometrics & Systems Pharmacology and Taylor & Francis, ensuring that the methodology section is as robust as the results.

From Code to Compliance: The Strategic Workflow

Modellers are often brilliant architects who struggle to explain the building to those who need to buy it. I act as the translator:

The Technical Audit: I review your model’s outputs, $C_{max}$ , $AUC$ , half-life ( $t_{1/2}$ ), and binding affinities, to ensure the narrative never over-reaches the math(s).
Visualising the Math(s): I coordinate with teams to ensure that graphs and tables (forest plots, VPCs, goodness-of-fit plots) align perfectly with the text.
Regulatory Narrative Framing: I ensure the “Strategic Clarity” of your submission, aligning the scientific findings with the commercial objectives of the drug development cycle.

Project Scope	Client/Partner	Outcome
Monoclonal Antibody Modeling	LYO-X AG	Drafted paper from scratch exploring half-life prolongation.
Chemoprophylaxis Methodology	MMV	Published predictive modeling methodology paper (Open Access).
Wet AMD Editorial Lead	Confidential (2025)	Coordinating the full writing and submission process (In-submission).
Malaria PKPD Model	MMV	Developed model incorporating multiple mosquito-bite scenarios.

Expertise Across the Lifecycle

My experience spans the entire drug development cycle, from preclinical safety testing to Phase 3 trials, e.g.:

Monoclonal Antibodies: Exploring mutations and binding options to prolong half-life.
Malaria Chemoprophylaxis: Developing predictive modeling methodology papers incorporating multiple mosquito-bite scenarios.
High-Stakes Therapeutics: Immunology, Oncology, and Ophthalmology, areas where precision is critical.

Don't let your model get lost in translation.

You’ve done the hard work of building the model. Let’s make sure the world understands its value. Whether you need a full manuscript from scratch or a strategic review of a regulatory submission, I speak your language.